Aimovig (erenumab or erenumab-aooe) is a medication that's used to prevent migraines in adults. It's convenient because it's available as a prefilled autoinjector or syringe, but it's important that you know how to inject the medication properly for it to work. Aimovig (erenumab) is available as a brand-name medication only and is given as an injection under your skin once a month. Possible side effects include pain, swelling, or redness at the injection site and constipation.
Prevention of migraines in adults
Aimovig (erenumab) is a monoclonal antibody that blocks proteins in the brain and nervous system called calcitonin gene-related peptide (CGRP) receptors. These proteins are thought to have a role in pain signaling and migraine symptoms. By blocking CGRP receptors, Aimovig (erenumab) might help prevent migraines.
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Taken only once per month
Can store at room temperature for up to 7 days, if needed (though typically refrigerated)
Available as a prefilled syringe and a prefilled autoinjector
Must give as an injection under the skin
Can't use in children
Some autoinjectors and syringes might have parts that are made with dry natural rubber, which can cause allergic reactions in people sensitive to latex.
You should receive training from your provider or pharmacist on how to give yourself Aimovig (erenumab). Make sure you know how to inject the medication to avoid accidentally hurting yourself or wasting the medication. Read the instructions for use for the 70 mg/mL autoinjector, 140 mg/mL autoinjector, or the prefilled syringe. Contact your pharmacist or provider if you have any questions.
Inject Aimovig (erenumab) under the skin into the fatty tissue of your thighs, stomach, or back of your upper arms. Never inject it into your muscle or vein.
Inject Aimovig (erenumab) one time per month. If you forget to take your dose at the time you normally do, inject the medication as soon as you remember. Then, continue to take Aimovig (erenumab) each month from the date of your last dose.
Keep Aimovig (erenumab) in the carton it comes in to protect it from light. Store it in the refrigerator, but don't freeze it. If needed, you can keep Aimovig (erenumab) at room temperature for up to 7 days. This might be helpful if you're traveling and don't have access to a refrigerator. But make sure that you don't put Aimovig (erenumab) back in the refrigerator after it's reached room temperature and throw away any medication that's been at room temperature for more than 7 days.
Before you take your Aimovig (erenumab) dose, take the medication out of the refrigerator and lay it on a flat surface to warm up for at least 30 minutes. Don't shake it or warm it up any other way since this can damage the medication.
Always check the medication solution to make sure it's either clear and colorless or slightly yellow before using it. If it's cloudy, discolored, or has particles (chunks), don't use it. Additionally, don't use Aimovig (erenumab) if any part of the syringe or autoinjector is broken, if it was dropped on the floor, or if the cap is missing. Otherwise, the medication might not be safe to use. Use a new syringe or autoinjector, and call the manufacturer at 1-800-772-6436 for a replacement.
Each Aimovig (erenumab) autoinjector or syringe provides a single dose of medication. After using each autoinjector or syringe, throw it away, even if there's still some medication left inside. Any leftover medication won't be enough for another full dose, and there aren't any preservatives to keep germs out of the medication once you open it.
Throw away the Aimovig (erenumab) autoinjector or syringe in a sharps container or something made of heavy-duty plastic, such as an empty milk carton or laundry detergent bottle. Don't throw away needles or syringes in your trash can. These steps help lower the risk of needlestick injuries. For more information on how to throw away your sharps container safely and guidance for your specific state, visit the FDA's website.
Aimovig (erenumab) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Risk factors: Known latex or rubber allergy
It's possible to have an allergic reaction to Aimovig (erenumab). These allergic reactions are typically mild and might look like an itchy rash on the skin. They can happen within hours of taking the medication, but can sometimes show up more than a week after your dose.
Some Aimovig (erenumab) prefilled autoinjectors and prefilled syringes have certain parts that are made with dry natural rubber. If you're allergic to latex or rubber, using these particular Aimovig (erenumab) prefilled autoinjectors and prefilled syringes can cause an allergic reaction. Let your provider know if you're allergic to latex and what your reaction to latex is.
If you have a serious or severe allergic reaction (e.g., hives, swelling of face or tongue, difficulty breathing) while taking Aimovig (erenumab), stop taking the medication and get medical help right away.
Risk factors: Taking other medications that worsen constipation
Aimovig (erenumab) can cause constipation with serious complications that can sometimes require hospitalization or even surgery. In the majority of cases that happened during clinical studies, constipation started after the first dose of Aimovig (erenumab). But it's possible to have constipation later on in treatment as well. The risk for severe constipation and its complications might be higher if you're taking other medications that cause constipation. If you get constipated while using Aimovig (erenumab), contact your provider.
Risk factors: History of high blood pressure
Aimovig (erenumab) can cause new or worsening high blood pressure. You're at risk if you already have high blood pressure or if you have risk factors for high blood pressure. Some people who experienced high blood pressure during Aimovig (erenumab) treatment needed to take blood pressure medications. And in some cases, elevations in blood pressure even led to hospitalization. While high blood pressure can happen anytime during treatment, it's more common to happen within a week of taking your Aimovig (erenumab) dose, particularly after your first dose. If you notice any symptoms of extremely high blood pressure (e.g., headache, chest pain, nosebleed, vision problems), call 911 right away.
The typical dose is 70 mg injected under the skin once per month. Your provider might raise your dose to 140 mg once per month depending on how you respond to the medication.
Prevention of migraines in adults
Migraine prevention
Episodic (occasional) cluster headaches
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
Ailani, J., et al. (2021). The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache.
Amgen Inc. (2024). Aimovig- erenumab-aooe injection; Aimovig- erenumab-aooe injection, solution [package insert]. DailyMed.
Amgen Inc. (2022). Instructions for use: Aimovig® (AIM-oh-vig) (erenumab-aooe) injection, for subcutaneous use single-dose prefilled SureClick® autoinjector 70 mg/mL .
Amgen Inc. (2024). Instructions for use: Aimovig® (AIM-oh-vig) (erenumab-aooe) injection, for subcutaneous use 70 mg/mL single-dose prefilled SureClick® autoinjector.
Amgen Inc. (2024). Instructions for use: Aimovig® (AIM-oh-vig) (erenumab-aooe) injection, for subcutaneous use 140 mg/mL single-dose prefilled SureClick® autoinjector.
Goadsby, P. J., et al. (2017). A controlled trial of erenumab for episodic migraine. The New England Journal of Medicine.
Mohanty, D., et al. (2020). CGRP inhibitors for migraine. Innovations in Clinical Neuroscience.
Tepper, S., et al. (2017). Safety and efficacy of erenumb for preventative treatment of chronic migraine: A randomised, double-blind placebo-controlled phase 2 trial. Lancet Neurology.
U.S. Food and Drug Administration. (2021). Safely using sharps (needles and syringes) at home, at work and on travel.
Vig, S. J., et al. (2022). The use of erenumab for migraine prophylaxis during pregnancy: A case report and narrative review. Headache.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.